India caps trade margins on cancer drugs, targeting 70% price cuts

India's government has moved to regulate profit margins in the distribution chain for non-scheduled cancer drugs, capping trade markups at 30% in a bid to make life-saving medications more affordable. The intervention is expected to drive down retail prices by as much as 70%, making cancer treatment accessible to a broader section of the population.

The price regulation targets the wholesale and retail distribution network rather than manufacturer pricing, addressing the layered costs that typically inflate final consumer prices. By streamlining margins across distribution channels, authorities aim to eliminate excessive markups while ensuring the supply chain remains economically viable.

The initiative is projected to generate annual patient savings of ₹2,500 crore, a substantial relief for families managing the substantial financial burden of cancer treatment. India bears one of the world's highest out-of-pocket healthcare expenses, with cancer drugs often representing catastrophic costs for middle and lower-income households.

The measure applies specifically to non-scheduled cancer medications, which fall outside existing price control frameworks. This targeted approach allows the government to address affordability challenges in the oncology sector while maintaining market dynamics in other pharmaceutical segments. Implementation details and a timeline for the new margin caps are expected to follow.